Healthcare technology startup Lucis has raised $20 million in Series A funding as it pushes deeper into the fast-growing preventive healthcare market in Europe. The company plans to use the investment to expand its AI-powered health platform and enter new European countries by the end of 2026.
The funding round was led by Singular, with participation from General Catalyst and Y Combinator. The new investment comes just months after Lucis secured an $8 million seed round, bringing the company’s total funding to nearly $28 million.
Lucis was founded in 2025 by Maxime Berthelot and Baptiste Debever. The startup focuses on preventive healthcare by helping users identify health risks early through blood biomarker analysis and artificial intelligence.
Lucis Focuses on Early Health Detection
The company’s platform analyzes more than 110 blood biomarkers related to cardiovascular health, hormones, inflammation, nutrition, and metabolic conditions. Users receive personalized health insights and lifestyle recommendations through Lucis’ AI-powered app.
According to the company, the platform combines blood test data with health history and medical research to generate recommendations aimed at improving long-term health outcomes. Lucis also works with medical professionals and laboratory partners to support its services.
The startup says its broader goal is to move healthcare toward prevention instead of waiting until diseases develop or worsen before treatment begins.
Rapid Expansion Across Europe
Since launching, Lucis has expanded its presence across France, the United Kingdom, Ireland, and Portugal. The company reports that it now serves more than 10,000 users across these markets.
Lucis also stated that it has delivered more than one million biomarker tests through its growing healthcare network. The company partners with laboratory groups, including Eurofins and Randox, to support testing operations.
The company shared that over 75% of users who completed six-month follow-ups showed improvements in at least three biomarkers without medication. Lucis also reported that more than 80% of users chose to retest after their initial analysis, reflecting continued engagement with the platform.
Funding to Support New Market Entry
With the new Series A funding, Lucis plans to expand into Spain, Germany, and Italy. The company will also continue investing in personalization tools, clinical safety systems, and AI capabilities designed to improve preventive healthcare services.
Investor interest in AI-driven healthcare platforms has increased sharply as startups explore ways to combine medical data, diagnostics, and artificial intelligence into personalized healthcare solutions.
Lucis is positioning itself as part of that growing market by offering users a platform focused on early detection, long-term monitoring, and preventive care across Europe.
